Abstract
Myocardial energy metabolism disorders are essential pathophysiology in sepsis-associated myocardial injury. Yet, the underlying mechanisms involving impaired mitochondrial respiratory function upon myocardial injury remain poorly understood. Here we identify an unannotated and cardiomyocyte-enriched long non-coding RNA, Cpat (cardiac-protector-associated transcript), that plays an important role in regulating the dynamics of cardiomyocyte mitochondrial tricarboxylic acid (TCA) cycle. Cpat is essential to the mitochondrial respiratory function by targeting key metabolic enzymes and modulating TCA cycle flux. Specifically, Cpat enhances the association of TCA cycle core components malate dehydrogenase (MDH2), citrate synthase (CS), and aconitase (ACO2). Acetyltransferase general control non-repressed protein-5 (GCN5) acetylates CS and destabilizes the MDH2-CS-ACO2 complex formation. Cpat inhibits this GCN5 activity and facilitates MDH2-CS-ACO2 complex formation and TCA cycle flux. We reveal that Cpat-mediated mitochondrial metabolic homeostasis is vital in mitigating myocardial injury in sepsis-induced cardiomyopathy, positioning Cpat as a promising therapeutic target for preserving myocardial cellular metabolism and function.
Introduction
Sepsis-induced cardiomyopathy (SCM) represents a critical complication of systemic infection, characterized by acute cardiac dysfunction and high mortality. Central to this pathology is the failure of mitochondrial energy production within cardiomyocytes. While the role of protein-coding genes in metabolic regulation is well-documented, the contribution of long non-coding RNAs (lncRNAs) to mitochondrial homeostasis during sepsis remains largely unexplored. This study identifies a novel lncRNA, Cpat (cardiac-protector-associated transcript), which acts as a metabolic shield by preserving the integrity of the mitochondrial tricarboxylic acid (TCA) cycle.
Discovery and Characterization of Cpat
To identify key regulatory lncRNAs in septic hearts, researchers performed transcriptome sequencing on a mouse model of cecal ligation and puncture (CLP)-induced sepsis. Among the differentially expressed transcripts, Cpat (identified as XR4938650) emerged as one of the most significantly downregulated lncRNAs in septic hearts compared to sham controls.
Further analysis revealed that Cpat is highly tissue-specific. Expression profiling across various organs demonstrated that Cpat is predominantly enriched in the heart, with minimal expression in other tissues such as the liver, lung, or kidney. Single-cell RNA sequencing confirmed that this enrichment is specific to cardiomyocytes, suggesting a specialized role in cardiac physiology.
Mechanism: Stabilizing the Mitochondrial Metabolon
The study uncovered a unique functional pathway for Cpat. Unlike many lncRNAs that remain in the nucleus, Cpat is actively transported from the nucleus to the mitochondria by transport proteins HuR, CRM1, and Pnpt1. Once inside the mitochondria, it serves as a molecular scaffold for the "metabolon"—a physical complex of TCA cycle enzymes including malate dehydrogenase (MDH2), citrate synthase (CS), and aconitase (ACO2).
Under septic stress, the acetyltransferase GCN5 targets Citrate Synthase for acetylation at specific lysine residues (K52, K366, K370). This modification acts as a destabilizing force, causing the MDH2-CS-ACO2 complex to disassemble and impairing the efficiency of the TCA cycle. Cpat prevents this collapse by binding to GCN5 and inhibiting its ability to acetylate CS. By maintaining the structural integrity of this metabolic assembly line, Cpat ensures continued ATP production and mitochondrial health.
Key Results and Therapeutic Potential
The functional importance of Cpat was validated through both loss-of-function and gain-of-function experiments:
- Survival and Function: Overexpression of Cpat using AAV9-mediated gene delivery significantly improved survival rates in septic mice and preserved cardiac contractile function, as evidenced by higher ejection fractions and fractional shortening.
- Reduced Injury: Treatment with Cpat led to a marked reduction in clinical markers of myocardial injury (CK-MB and cTnT) and systemic inflammatory cytokines (IL-1β, TNF-α).
- Metabolic Rescue: Mitochondrial oxygen consumption rates (OCR) were restored in Cpat-treated septic hearts, confirming the rescue of respiratory function.
Discussion and Future Directions
This research identifies Cpat as a critical regulator of cardiac mitochondrial metabolism. By inhibiting GCN5-mediated acetylation of Citrate Synthase, Cpat maintains the TCA cycle flux necessary for cardiac survival during sepsis. While these findings are promising, future work must address the long-term safety of Cpat overexpression and its potential efficacy in other forms of heart failure, such as myocardial infarction. Given the high conservation of the Cpat sequence in humans, this pathway represents a compelling target for the development of RNA-based therapeutics for sepsis-induced cardiomyopathy.
Summary updated